Pier Luigi Zinzani, MD, PhD - Recognising and Responding to a Rare Disease: A Case-Based Exploration of the Ideal iMCD Patient Journey - PeerVoice Oncology & Haematology Audio | Lyssna här | Poddtoppen.se
Fler avsnitt av Pier Luigi Zinzani, MD, PhD - Recognising and Responding to a Rare Disease: A Case-Based Exploration of the Ideal iMCD Patient Journey
Marwan Fakih, MD - Making a Difference in Refractory Metastatic Colorectal Cancer: Practical Strategies to Positively Impact the Patient Journey Across Practice Settings
2026-05-27 |
28 min
+
Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer
2026-05-27 |
54 min
+
Martin Köbel, MD - Scoring Folate Receptor-Alpha Expression in Gynecological Cancers: An Interactive Pathology Masterclass
2026-05-19 |
29 min
+
Pier Luigi Zinzani, MD, PhD - Recognising and Responding to a Rare Disease: A Case-Based Exploration of the Ideal iMCD Patient Journey
2026-03-26 |
20 min
+
Austin Kulasekararaj, MD, MRCP, FRCPath - From Life-Threatening to Life-Optimised: The Evolving Management of Paroxysmal Nocturnal Haemoglobinuria Across the Complement Cascade
2026-03-26 |
29 min
+
Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era
2026-03-07 |
40 min
+
Cristina Saura Manich, MD, PhD - First-Line Treatment of HER2-Positive Metastatic Breast Cancer: Could Investigational Approaches Improve on Current Standard of Care?
2026-02-26 |
19 min
+
Matthew J. Koster, MD - VEXAS Syndrome Asked and Answered: Everything You Want To Know And More
2026-02-26 |
28 min
+
Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings
2026-01-08 |
21 min
+
Steven Horwitz, MD - Relapsed/Refractory Peripheral T-Cell Lymphoma: Reviewing Available and Anticipated Strategies in This Rare Malignancy
2025-12-18 |
20 min
+
Podden och tillhörande omslagsbild på den här sidan tillhör
PeerVoice. Innehållet i podden är skapat av PeerVoice och inte av,
eller tillsammans med, Poddtoppen.
En ny version av sidan finns tillgänglig.
Ladda om
Stäng
